In Depth A half-billion-dollar bid to head off emerging diseases

In the wake of the Ebola crisis that erupted in West Africa in 2014, many public health leaders recognized that a more aggressive effort to develop vaccines could have moved a vaccine forward more quickly and prevented that outbreak from becoming an epidemic. A new organization was formed last year, the Coalition for Epidemic Preparedness Innovations (CEPI), to speed development of vaccines against emerging infectious diseases—but it had no serious financial backing. Now, CEPI has attracted nearly a half-billion dollars in funding, as it planned to announce at the World Economic Forum in Davos, Switzerland, this week. The Bill &Melinda Gates Foundation and the Wellcome Trust each donated $100 million, and the governments of Norway, Japan, and Germany make up the balance. CEPI also decided to focus initially on three diseases—Lassa, Nipah, and Middle East respiratory syndrome–coronavirus—and it will soon seek proposals from academia and industry to make these vaccines and conduct early phase trials so that they're at the ready for a real-word efficacy test when these pathogens emerge. Author: Jon Cohen
Source: ScienceNOW - Category: Science Authors: Tags: Public Health Source Type: news

Related Links:

Publication date: Available online 18 November 2019Source: Antiviral ResearchAuthor(s): Wanyu Dong, Wenting Xie, Yunbo Liu, Baokun Sui, Hao Zhang, Liran Liu, Yubei Tan, Xiaohan Tong, Zhen F. Fu, Ping Yin, Liurong Fang, Guiqing PengAbstractEmerging coronaviruses (CoVs) primarily cause severe gastroenteric or respiratory diseases in humans and animals, and no approved therapeutics are currently available. Here, A9, a receptor tyrosine kinase inhibitor (RTKI) of the tyrphostin class, is identified as a robust inhibitor of transmissible gastroenteritis virus (TGEV) infection in cell-based assays. Moreover, A9 exhibited potent ...
Source: Antiviral Therapy - Category: Virology Source Type: research
Microbial Drug Resistance, Ahead of Print.
Source: Microbial Drug Resistance - Category: Microbiology Authors: Source Type: research
Applied Physiology, Nutrition, and Metabolism, e-First Articles. Gestational fructose exposure has detrimental health consequences on both the maternal and fetus or offspring in the early or later life, contributing to epidemic rise in cardiometabolic syndrome including cardiac events. l-Glutamine has been shown to mitigate cardiac metabolic stress. However, the effect of l-glutamine on cardiac hypertrophy induced by gestational fructose exposure is not known. We therefore hypothesized that l-glutamine would prevent gestational fructose-induced cardiac hypertrophy, possibly by suppression of pyruvate dehydrogenase kinase-4...
Source: Applied Physiology, Nutrition, and Metabolism - Category: Physiology Authors: Source Type: research
Publication date: Available online 18 November 2019Source: Fish &Shellfish ImmunologyAuthor(s): Defeng Zhang, Yanxia Gao, Qingyong Li, Xiaoli Ke, Zhigang Liu, Maixin Lu, Cunbin ShiAbstractStreptococcus agalactiae is an important pathogen associated with various aquatic animals, especially tilapia. Streptococcosis has greatly limited the healthy development of tilapia aquaculture in recent times. The development of novel effective vaccines is important for the prevention and control of streptococcosis in fish. We previously constructed a non-encapsulated S. agalactiae strain △cps by the in-frame deletion method. Here,...
Source: Fish and Shellfish Immunology - Category: Biology Source Type: research
In this study, an NDV isolate APMV-1/Chicken/China (SC)/PT3/2016 (hereafter referred as PT3) was identified as a class Ⅰ NDV and a lentogenic strain. The antigenic relationship between PT3 and 3 other NDV strains, including vaccine strain LaSota and 2 prevalent genotype Ⅶd and Ⅵb strains were analyzed. The protective efficacy of PT3 and LaSota against challenge with genotype Ⅶd and Ⅵb strains were assessed. The antigenic analysis result showed that 4 strains belong to the single serotype and the PT3 antiserum exhibited the highest HI titer against 3 other NDV strains. The results of protective efficacy showed tha...
Source: Biologicals - Category: Biology Source Type: research
Publication date: November 2019Source: Chinese Journal of Analytical Chemistry, Volume 47, Issue 11Author(s): Can-Can ZHU, Jun-Sheng CUI, An-Zhong HU, Ke YANG, Jun ZHAO, Yong LIU, Guo-Qing DENG, Ling ZHUAbstractInfectious diseases caused by highly pathogenic microorganisms are the main factors threatening human health and causing social panic. To simultaneously detect bacteria and viruses in a single test, a PCR-Array chip based on solid phase PCR (SP-PCR) was developed, in which an ultraviolet cross-linking method was used to fix oligonucleotide sequence on the grass to develop a PCR array chip for detection of Crimea-Con...
Source: Chinese Journal of Analytical Chemistry - Category: Chemistry Source Type: research
In Middleton, Wisconsin, an NSF-supported small business is expanding on ways to make everything from biopesticides to vaccines – all on the surface of leaves! How does this innovative approach to chemical manufacturing help us use the greenest, most renewable chemical factories on earth? Ryan and ...This is an NSF Multimedia Gallery item.
Source: NSF Multimedia Gallery - Category: Science Source Type: video
Ebola. MERS. Zika. Nipah virus. Lassa fever. Rift Valley fever. All were in active outbreaks in June.
Source: Science - The Huffington Post - Category: Science Source Type: news
A global coalition of governments, health specialists and philanthropists will launch a new plan on Thursday to “outsmart” future disease epidemics with a fund to prepare and create new vaccines. Stung by the devastation of West Africa’s 2014-2015 Ebola outbreak, which killed more than 11,300 people before an effective vaccine was developed, the coalition is aiming to ensure such deadly outbreaks can’t happen again. John-Arne Rottingen, interim chief executive officer of the Coalition for Epidemic Preparedness Innovations (CEPI), said it is designed as “a global insurance policy against epidem...
Source: Healthy Living - The Huffington Post - Category: Consumer Health News Source Type: news
Lassa, Mers and Nipah will be first diseases targeted by programme announced at Davos by coalition of governments, philanthropists and businessA coalition of governments, philanthropists and business is pledging to put money and effort into making vaccines to stop the spread of diseases that could threaten mankind – and to prevent another outbreak as devastating as the Ebola epidemic.At theWorld Economic Forum in Davos, the Norwegian, Japanese and German governments, the Wellcome Trust and the Gates Foundation announced they were putting in $460 million – half of what is needed for the first five years of the i...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Vaccines and immunisation Infectious diseases Davos Health Epidemics Medical research Business Science Society World news Source Type: news
More News: Academia | African Health | Ebola | Ebola Vaccine | Epidemics | Epidemiology | Funding | International Medicine & Public Health | Lassa Fever | MERS | Middle East Health | Nipah Virus | Outbreaks | Respiratory Medicine | Vaccines